ABSTRACT
Gluconobacter belongs to the acetic acid bacteria (AAB), which are microorganisms commonly found in the environment and used in the food industry. These bacteria have increasingly been reported as organisms that can potentially infect humans. We report a case of Gluconobacter spp. bloodstream infection associated with endocardial lesions in a 25 year-old female intravenous drug abuser. To the best of our knowledge, this is the first case of Gluconobacter spp. endocarditis reported in the literature. For the first time we report that a multiresistant strain belonging to the genus Gluconobacter can cause endocarditis, giving evidence to the fact that this microorganism should be considered a new opportunistic human pathogen.
Subject(s)
Endocarditis, Bacterial/complications , Endocarditis, Bacterial/microbiology , Gluconobacter/isolation & purification , Substance Abuse, Intravenous/complications , Adult , Bacteremia/complications , Bacteremia/diagnosis , Bacteremia/microbiology , Drug Resistance, Multiple, Bacterial , Endocarditis, Bacterial/diagnosis , Female , Gluconobacter/classification , Gluconobacter/drug effects , Gluconobacter/genetics , Gram-Negative Bacterial Infections/complications , Gram-Negative Bacterial Infections/diagnosis , Gram-Negative Bacterial Infections/microbiology , Humans , Microbial Sensitivity TestsABSTRACT
BACKGROUND: Community-acquired bacterial pneumonia (CABP) represents an important cause of morbidity and mortality for cirrhotic and HIV-infected patients, respectively. However, little is known on CABP in HIV-positive patients with cirrhosis. A study was performed to describe the clinical features and factors predictive of mortality and prolonged hospitalization in cirrhotic HIV-infected patients with a diagnosis of CABP. METHODS: Demographic and clinical characteristics of cirrhotic HIV-positive subjects, hospitalized for CABP in our department from June 2000 to December 2006, were compared with those of non-cirrhotic HIV-infected patients with the same diagnosis hospitalized from June 2000 to November 2001. Variables with p < 0.10 in univariate analysis were tested for their predictive value for mortality and length of hospitalization with uni- and multivariate logistic regression analysis. RESULTS: Twenty-nine cirrhotic and 73 non-cirrhotic HIV-positive patients with CABP were compared. Age and alcohol abuse were significantly higher in cirrhotics. At hospital admission, cirrhotic patients had more frequently mental status alterations (7.26 [2.21-23.82], p = 0.001) and milder symptoms and signs (temperature > 37.5 C: 0.27 [0.10-0.75], p = 0.01; respiratory rate > 20: 0.34 [0.13-0.92], p = 0.033; systemic inflammatory response syndrome (SIRS): 0.39 [0.16-0.95], p = 0.038). Adjusting for age, cirrhosis was associated with a higher mortality (5.96 [1.05-33.57]; p = 0.043). Adjusting for age, gender, and concomitant antiretroviral treatment, cirrhosis was also associated with a prolonged hospitalization (> 7 days: 9.30 [1.84-46.82]; p = 0.007). CONCLUSION: The diagnosis of CABP can be difficult in cirrhotic HIV-positive patients because clinical presentation is milder. However, CABP needs to be promptly recognized because mortality is higher in these patients.
Subject(s)
Community-Acquired Infections/epidemiology , Community-Acquired Infections/physiopathology , HIV Infections/complications , Liver Cirrhosis/complications , Pneumonia, Bacterial/epidemiology , Pneumonia, Bacterial/physiopathology , Risk Factors , Adult , Community-Acquired Infections/mortality , Female , Hospitalization , Humans , Length of Stay , Male , Middle Aged , Pneumonia, Bacterial/mortalityABSTRACT
Clinical stability (CS), defined as normalization of vital signs, is often used to manage inpatients with community-acquired pneumonia (CAP). The main objective of our study was to identify a reliable definition of CS for human immunodeficiency virus (HIV)-positive patients with CAP. During an 18-month period, 437 HIV-positive Italian inpatients with CAP were enrolled in the study. We used 3 definitions of CS (from a less conservative [definition 1] to a more conservative [definition 3] definition) based on combinations of different thresholds for vital signs. Assessments were performed at admission and daily during the hospital stay. For the 3 definitions, 14.9%, 8.0%, and 4.8% of patients were stable at baseline, with deterioration after reaching CS in 7.16%, 4.76%, and 2.05%, respectively. The 8 patients whose conditions deteriorated after reaching CS definition 3 (systolic blood pressure, >90 mm Hg; pulse, <90 beats/min; respiratory rate, <20 breaths/min; oxygen saturation, >90%; temperature, <37 degrees C; ability to eat; and normal mental status) survived and were discharged from the hospital. The more conservative definition of CS appears to be reliable for the management of HIV-infected patients with CAP.
Subject(s)
Community-Acquired Infections/complications , HIV Infections/complications , Pneumonia/complications , Adult , Community-Acquired Infections/mortality , Female , HIV , HIV Infections/mortality , Humans , Male , Pneumonia/mortalityABSTRACT
We describe a patient with early post-surgical infective endocarditis due to methicillin-resistant Staphylococcus aureus, who was unsuitable for surgical reintervention and who failed standard antistaphylococcal therapy, but was successfully cured with a sequential regimen including quinupristin/dalfopristin and linezolid.
Subject(s)
Acetamides/pharmacology , Anti-Infective Agents/pharmacology , Drug Therapy, Combination/pharmacology , Endocarditis, Bacterial/drug therapy , Oxazolidinones/pharmacology , Staphylococcal Infections/drug therapy , Surgical Wound Infection/drug therapy , Virginiamycin/pharmacology , Aged , Aged, 80 and over , Cardiovascular Surgical Procedures/adverse effects , Drug Administration Schedule , Endocarditis, Bacterial/etiology , Female , Humans , Linezolid , Methicillin Resistance , Mitral Valve Insufficiency/surgery , Staphylococcal Infections/etiology , Surgical Wound Infection/etiologySubject(s)
Acetamides/cerebrospinal fluid , Anti-Infective Agents/cerebrospinal fluid , Antibiotic Prophylaxis , Central Nervous System Infections/cerebrospinal fluid , Oxazolidinones/cerebrospinal fluid , Postoperative Complications/cerebrospinal fluid , Acetamides/pharmacokinetics , Acetamides/therapeutic use , Anti-Infective Agents/pharmacokinetics , Anti-Infective Agents/therapeutic use , Central Nervous System Infections/drug therapy , Humans , Linezolid , Meningitis, Bacterial/cerebrospinal fluid , Meningitis, Bacterial/drug therapy , Oxazolidinones/pharmacokinetics , Oxazolidinones/therapeutic use , Postoperative Complications/microbiologySubject(s)
Cross Infection/etiology , Cross Infection/pathology , Mycobacterium Infections, Nontuberculous/complications , Mycobacterium Infections, Nontuberculous/pathology , Mycobacterium chelonae/pathogenicity , Travel , Adult , Humans , Italy , Male , Surgical Wound Infection/etiology , Surgical Wound Infection/pathologyABSTRACT
The purpose of this study was to evaluate the pharmacokinetics (PK) profile of oral levofloxacin in human immunodeficiency virus-positive patients in steady-state treatment with nelfinavir (NFV) or with efavirenz (EFV) and to determine the effects of levofloxacin on the PK parameters of these two antiretroviral agents. For levofloxacin, plasma samples were obtained at steady state during a 24-h dosing interval. Plasma NFV and EFV concentrations were evaluated before and after 4 days of levofloxacin treatment. Levofloxacin PK do not seem affected by NFV and EFV. There was no significant difference between NFV and EFV plasma levels obtained with and without levofloxacin.